Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist
Author(s) -
Hugh S. Taylor,
Linda C. Giudice,
Bruce A. Lessey,
Maurício Simões Abrão,
Jan Kotarski,
David F. Archer,
Michael P. Diamond,
Eric S. Surrey,
Neil P. Johnson,
Nelson B. Watts,
John C. Gallagher,
James A. Simon,
Bruce R. Carr,
W. Paul Dmowski,
Nicholas Leyland,
J.P. Rowan,
W. Rachel Duan,
Juki Ng,
Brittany Schwefel,
James W. Thomas,
Rita I. Jain,
Kristof Chwalisż
Publication year - 2017
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1700089
Subject(s) - medicine , endometriosis , antagonist , hormone antagonist , gonadotropin releasing hormone , gonadotropin releasing hormone antagonist , gynecology , hormone , luteinizing hormone , receptor
Endometriosis is a chronic, estrogen-dependent condition that causes dysmenorrhea and pelvic pain. Elagolix, an oral, nonpeptide, gonadotropin-releasing hormone (GnRH) antagonist, produced partial to nearly full estrogen suppression in previous studies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom